CAR T-Cell Therapy: High Risk, High Reward Part 2

| January 24, 2017

article image
As discussed in Part 1 of this blog series, Chimeric Antigen Receptor (CAR) T-cells are having an incredible impact on the cell therapy industry.  However, despite the many success stories, there are also several items that require consideration if we are to truly harness the potential of this type of therapy.  Let’s begin by exploring some of the unresolved questions and issues surrounding CAR T-cell therapy.

Spotlight

Molecular NeuroImaging

Molecular NeuroImaging provides neuroimaging research services to the pharmaceutical and biotech industries. By focusing on developing radioligands as tools for human research, we will improve early diagnosis and rapid drug development for neurodegenerative and neuropsychiatric disorders. MNI key activities: * Radioligand development * Early phase human drug-trials-displacement/occupancy * Large scale Phase II-IV clinical imaging trials. * Multi-center quantitative imaging trials - Clinical imaging site coordination as a technical CRO - Core image processing laboratory * Biomarker development – presymptomatic and disease progression.

OTHER ARTICLES

Learning How FoxA2 Helps Turn Stem Cells into Organs

Article | March 18, 2020

Scientists at the Perelman School of Medicine at the University of Pennsylvania discovered early on in each cell, FoxA2 simultaneously binds to both the chromosomal proteins and the DNA, opening the flood gates for gene activation. The discovery, “Gene network transitions in embryos depend upon interactions between a pioneer transcription factor and core histones,” published in Nature Genetics, helps untangle mysteries of how embryonic stem cells develop into organs, according to the researchers. “Gene network transitions in embryos and other fate-changing contexts involve combinations of transcription factors. A subset of fate-changing transcription factors act as pioneers; they scan and target nucleosomal DNA and initiate cooperative events that can open the local chromatin. However, a gap has remained in understanding how molecular interactions with the nucleosome contribute to the chromatin-opening phenomenon,” write the investigators.

Read More

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | April 17, 2020

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More

Closing bacterial genomes from the human gut microbiome using long-read sequencing

Article | February 12, 2020

In our lab, we focus on the impact of the gut microbiome on human health and disease. To evaluate this relationship, it’s important to understand the particular functions that different bacteria have. As bacteria are able to exchange, duplicate, and rearrange their genes in ways that directly affect their phenotypes, complete bacterial genomes assembled directly from human samples are essential to understand the strain variation and potential functions of the bacteria we host. Advances in the microbiome space have allowed for the de novo assembly of microbial genomes directly from metagenomes via short-read sequencing, assembly of reads into contigs, and binning of contigs into putative genome drafts. This is advantageous because it allows us to discover microbes without culturing them, directly from human samples and without reference databases. In the past year, there have been a number of tour de force efforts to broadly characterize the human gut microbiota through the creation of such metagenome-assembled genomes (MAGs)[1–4]. These works have produced hundreds of thousands of microbial genomes that vastly increase our understanding of the human gut. However, challenges in the assembly of short reads has limited our ability to correctly assemble repeated genomic elements and place them into genomic context. Thus, existing MAGs are often fragmented and do not include mobile genetic elements, 16S rRNA sequences, and other elements that are repeated or have high identity within and across bacterial genomes.

Read More

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | February 18, 2020

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More

Spotlight

Molecular NeuroImaging

Molecular NeuroImaging provides neuroimaging research services to the pharmaceutical and biotech industries. By focusing on developing radioligands as tools for human research, we will improve early diagnosis and rapid drug development for neurodegenerative and neuropsychiatric disorders. MNI key activities: * Radioligand development * Early phase human drug-trials-displacement/occupancy * Large scale Phase II-IV clinical imaging trials. * Multi-center quantitative imaging trials - Clinical imaging site coordination as a technical CRO - Core image processing laboratory * Biomarker development – presymptomatic and disease progression.

Events